These payer-imposed policies — including prior authorization, step-therapy protocols and restrictive formularies — often restrict or deny specific therapies to patients due to cost, according to the report.
“[P]olicies that attempt to incentivize, force or coerce patients to accept anti-cancer therapy alternatives that are not recommended by their oncologist can threaten
both the outcomes for patients and the well-being of their families or caretakers,” the ASCO said.
In the statement, the ASCO reviews current management policies payers use to control the cost of cancer drugs and recommends ways to ensure these policies don’t undermine high-value patient care.
To view the full report, click here.
More articles on supply chain:
Global pharmerging market to reach $1.4B by 2025
FDA OKs Tecentriq for advanced bladder cancer
Bristol-Myers will license drugs to Biogen, Roche for $470M
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.